Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis

Gastroenterology. 2020 Nov;159(5):1985-1987.e4. doi: 10.1053/j.gastro.2020.07.050. Epub 2020 Aug 5.
No abstract available

Keywords: Cirrhosis; Fibrosis; High-risk population; NASH; Screening.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cost-Benefit Analysis
  • Diabetes Mellitus, Type 2 / diagnosis
  • Diabetes Mellitus, Type 2 / economics*
  • Diabetes Mellitus, Type 2 / epidemiology
  • Diabetes Mellitus, Type 2 / therapy
  • Diagnostic Screening Programs / economics*
  • Health Care Costs*
  • Healthy Lifestyle
  • Humans
  • Liver Cirrhosis / diagnosis
  • Liver Cirrhosis / economics
  • Liver Cirrhosis / epidemiology
  • Markov Chains
  • Models, Economic
  • Non-alcoholic Fatty Liver Disease / diagnosis*
  • Non-alcoholic Fatty Liver Disease / economics*
  • Non-alcoholic Fatty Liver Disease / epidemiology
  • Non-alcoholic Fatty Liver Disease / therapy
  • Predictive Value of Tests
  • Quality of Life
  • Quality-Adjusted Life Years
  • Reproducibility of Results
  • Risk Factors
  • Risk Reduction Behavior
  • Treatment Outcome
  • United States / epidemiology